Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
decitabine + toripalimab
- Development stage
- Unknown
- Lead developer
- Junshi Biosciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Decitabine + toripalimab is a combination therapy consisting of the hypomethylating agent decitabine and the anti-PD-1 monoclonal antibody toripalimab. Decitabine is a DNA methyltransferase inhibitor that induces the re-expression of silenced genes, including those involved in antigen presentation and immune recognition. This epigenetic modification is hypothesized to sensitize tumor cells to immune checkpoint inhibition. Toripalimab is a humanized monoclonal antibody that targets the Programmed Cell Death Protein 1 (PD-1) receptor on T cells, blocking its interaction with ligands PD-L1 and PD-L2 to restore anti-tumor immune responses. The combination is primarily being investigated for the treatment of hematological malignancies, such as recurrent or refractory follicular lymphoma, where epigenetic priming may overcome resistance to immunotherapy.
- Brand names
- Tuoyi
- Other names
- decitabine + triprizumabdecitabine + triplezumablow-dose decitabine + toripalimab
02
Targets
DNMT1 (DNA (cytosine-5)-methyltransferase 1)PDCD1 (Programmed cell death protein 1 receptor)DNMT3B (DNA (cytosine-5)-methyltransferase 3B)DNMT3A (DNA methyltransferase 3 alpha)
Beyond the preview
Go deeper on decitabine + toripalimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on decitabine + toripalimab.